Pies sometimes a company prepares for market other times the market comes to them.
That being said, although the biabetic nephropathy 2a results showed the fundamentals of both safety and efficiency plus dosage optimisation it’s the FSGS that pushed the appeal towards an entry position, hence now a shareholders.
One further point many here have recently touched on, that of a licensing/ takeover deals. They take time via negotiation and further negotiations.
The current 2a results in nephrology by DXB may have already caught the eye of big pharma or simply may not. What is more certain though (hopefully a tight ship concept applying) is regardless of SP fluctuations and/or posts on hot copper by anyone (self included) it is in the hands of management on behalf of all shareholders to negotiate extensively in favour of before it hits the board for decision.
P.s my reasons for the rare disease (FSGS) excitement are on a previous post, but I should add that these niche markets are most value negotiating of all.
Others?
Add to My Watchlist
What is My Watchlist?
